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"Once there is a union of sperm and egg, what you have is a living entity
with a full and unique genetic character. There shouldn't be a moral
coarsening of appreciation for life that allows us to think of it as nothing. .. )
Robert Royal
"From the time that the ovum is fertilized, a new life is begun which is
neither that of the father or the mother; it is rather the life of a new human
being with his own growth. It would never be made human if it were not
human already. To this perpetual evidence .... modern genetic science
brings valuable confirmation. It has demonstrated that from the first
instant, the program is fixed as to what this living being will be: a man, this
individual man with his characteristic aspects already well determined.
Right from fertilization is begun the adventure of a human life, and each of
its great capacities requires time .... to find its place and to be in a position
to act...2
Congregationfor the Doctrine of the Faith
Declaration on Procured Abortion, 12-13
While still in office, President Clinton gave instructions to Dr. Harold
Shapiro, Chair of the National Bioethics Advisory Committee (NBAC) to
undertake a thorough review of the issues associated with human stem cell
research. The dangerous conclusion of the NBAC was that ''this research is
allied with a noble cause, and any taint that might attach from the source of
stem cells diminishes in proportion to the potential good which the research
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may yield.,,3 This is classic situation ethics where the ends justify the
means.
Researchers at the University of Wisconsin and Johns Hopkins
University have successfully isolated and cultured human primordial stem
cells. These stem cells have been shown to be building blocks for almost
all human tissue. These pluripotent cells apparently have the capacity to
differentiate into any of the human cell types. If their differentiation can be
controlled, they could be used to grow healthy tissue that would augment or
replace diseased tissues. Scientists believe this potential raises the
possibility of growing spare body parts or correcting such disorders as
diabetes, heart disease, cancer, and Parkinson' s disease.
At the same time, we must consider how these stem cells are obtained.
The isolation of stem cells involves the extraction and manipulation of cells
harvested from the inner mass of blastocysts, a fluid-filled sphere made up
of cells that will become the placenta, and 15-20 cells clinging together and
to the inside of the blastocyst wall that will become the embryo. These
inner cells will give rise to embryonic stem cells each identical to the
others, and each able to become any kind of cell in the human body. These
cell lines are derived from discarded or frozen embryos. Stem cells may be
harvested from the gonadal tissue of aborted fetuses, rekindling the debate
about the moral status of these entities and what we may ethically do with
and to them. These studies raise questions about the interplay between
private funding and public oversight of morally contested research.
The Wisconsin group, led by James A. Thompson, published its work
in the November 6, 1998 issue of Science. The "research and clinical
potential for human embryonic stem cells is enormous," he writes. They
will be used for studies of normal and abnormal human embryo
development (birth defects), to test new drugs and especially "as a
renewable source of cells for tissue transplantation, cell replacement and
gene therapies.'.4 Thompson used blastocysts left over from in vitro
fertilizations that would have been discarded.
The donors of the
blastocysts gave permission for them to be used in research.
The Geron Corp. Ethics Advisory Board recently declared that human
embryonic stem cell lines not originating with fetal tissue are obviously
below the threshold for independent moral standing. The problem in
applying EAB's "threshold" criterion of value is that no obvious threshold
exists. The human being must be respected as a person from the very first
instant of its existence. Respect for the dignity of the human being
excludes all experimental manipulation or exploitation of the human
embryo. The practice of keeping alive human embryos in vivo or in vitro
for experimental or commercial purposes is totally opposed to human

310

Linacre Quarterly

dignity. It is immoral to produce human embryos destined to be exploited
as disposable "biological materia\."
The freezing of embryos, even when carried out in order to
preserve the life of an embryo - cryopreservation - constitutes an
offense against the respect due to human beings by exposing them
to grave risks of death or harm to their physical integrity and
denying them, at least temporarily, maternal shelter and gestation,
thus placing them in a situation in which further offenses and
manipulation are possible. S

The excitement over the potential medical utility of embryonic stem
cells obscures the important issues about the scientific use and commercial
exploitation of human tissue. Geron Corp. financed research that derived
stem cells from aborted fetuses and from donated human embryos left over
from in vitro fertilization. The hypocrisy cries out when the Geron EAB
concludes that it is wrong for couples to sell their embryos. The same
arguments are used to argue that donors should not share in the profits
resulting from research on their embryos.
If it is wrong to commercialize embryos because of their nature, then
it is wrong for everyone. It is simply inconsistent to argue that couples
should act altruistically because commercializing embryos is wrong, while
permitting corporations and scientists to profit financially from cells
derived by destroying those embryos.
The Geron EAB addresses the issue of global justice and the
emerging world order, and the dangers of marketplace values, which often
dominate the way power is deployed and human problems addressed. It
fails miserably, though, in considering such issues as human dignity and
inviolability, the value of the human embryo, and non-commodification of
human life. It sets no concrete limit on the commercial exploitation of
embryo and genetic research. 6 In Europe, restrictions on cloning, embryo
research and reproductive technologies apply to all relevant activities,
whether privately or publicly funded.
There are morally acceptable alternatives to the use of embryonic
stem cells. New research involving adult stem cells and other advances in
repair and regeneration of human tissue offer the promise that embryonic
stem cells may simply be irrelevant to future medical progress. In the last
two years there have been startling advances in isolating and culturing adult
stem cells and even in the possibilities for dedifferentiating and
redifferentiating them to produce a broader array of different cells and
tissues. 7 Advances in the use of growth factors to grow new blood vessels
and nerve tissue and in the use of enzymes such as telomerase to
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"immortalize" useful cell cultures also offer enormous promise, both in
their own right and in combination with new knowledge about adult stem
cells. 8
The issue of cell "immortal ity" is at the heart of this matter. The ends
of chromosomes are sections of DNA called telomeres. They get a little
shorter each time a cell divides until finally they hit a critical length that
signals the cell to stop dividing. In January, 1998, Geron biologists
reported that an enzyme called telomerase can keep the telomeres from
shrinking, allowing cells to live and divide indefinitely (A characteristic
which is also possessed by cancer cells.). Telomerase is active in
embryonic stem cells, which as noted above can live and divide forever.
When those cells start to differentiate into specific cells for specific organs,
the telomorase disappears. The company is trying to find ways to make it
reappear so it will work against the deterioration associated with aging. It
is also looking for ways to block telomerase in treating cancer. An enzyme,
tankyrase was isolated at Rockefeller University and scientists believe that
it may control telomerase functioning.
The moral problem of encouraging the destruction of human embryos
for their stem cells is independent of any possible benefit expected from
such research. Established by the Nuremberg Code, ethical norms on
human experimentation have a demand that we never inflict death or
disabling injury on any unconsenting individual of the human species
simply for the sake of benefit to others. Stem cell research requiring the
destruction and sacrifice of human embryos should not be supported by the
government or supported by tax dollars. The existence of morally
acceptable alternatives that do not involve the destruction of human life for
research purposes would support the conclusion that support for embryo
research is unethical, for it needlessly relies on the destruction of life to
advance medical goals which can be achieved "in nondestructive ways.
Contentious as the issue is, there are signs that public opinion may
move toward support of at least limited embryo research. "Patients and
their families faced with disabling diseases want science to move as
quickly as possible," said Daniel Perry, executive of the Alliance for Aging
Research. 9 He heads a coalition of patient groups advocating research on
embryonic stem cells. It must become clear to these organizations that
while we have a moral obligation to the future health and welfare of
people, we cannot and should not violate our motal obligation to the
unborn . Human life is most vulnerable when it enters the world and when
it leaves the realm of time to embark on eternity. Let us protect life
throughout its miraculous development.
"Before I formed you in the womb I knew you, and before you were
born I consecrated you," (Jer. 1:5).
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